ArticleJNCI cancer spectrum2018
Epidemiology, Biology, Treatment, and Prevention of Ductal Carcinoma In Situ (DCIS).
Article in JNCI cancer spectrum, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 29 citations in OpenAlex.
- Nanoluciferase-CD63 labeling reveals extracellular vesicle kinetics in a mouse intraductal model of ductal carcinoma in situ.Breast cancer research : BCR · 2026Article
- Patient-reported Outcomes After Routine Treatment of In Situ/Atypical Lesions: The PORTAL Study.Annals of surgical oncology · 2025Article
- Insights from a multi-institutional registry show duration of endocrine treatment for DCIS impacts second events.NPJ breast cancer · 2025Article
- B cells and energy metabolism in HER2-positive DCIS: insights into breast cancer progression from spatial-omics analyses.Breast cancer research : BCR · 2025Article
- Association of DCIS size and margin status with risk of developing breast cancer post-treatment: multinational, pooled cohort study.BMJ (Clinical research ed.) · 2023Article
- The Senologic International Society Survey on Ductal CarcinomaEuropean journal of breast health · 2022Article
- Insights into Immune Escape During Tumor Evolution and Response to Immunotherapy Using a Rat Model of Breast Cancer.Cancer immunology research · 2022Article
- Article
- Histopathological growth distribution of ductal carcinoma in situ: tumor size is not "one size fits all".Gland surgery · 2022Article
- Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.International journal of clinical oncology · 2022Article
- HER2-Overexpressing Ductal CarcinomaCancer prevention research (Philadelphia, Pa.) · 2020Article
- Everolimus Inhibits the Progression of Ductal CarcinomaClinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
Abstract
Ductal carcinoma in situ (DCIS) is a highly heterogeneous disease. It presents in a variety of ways and may or may not progress to invasive cancer, which poses challenges for both diagnosis and treatment. On May 15, 2017, the Dana-Farber/Harvard Cancer Center hosted a retreat for over 80 breast specialists including medical oncologists, surgical oncologists, radiation oncologists, radiologists, pathologists, physician assistants, nurses, nurse practitioners, researchers, and patient advocates to discuss the state of the science, treatment challenges, and key questions relating to DCIS. Speakers and attendees were encouraged to explore opportunities for future collaboration and research to improve our understanding and clinical management of this disease. Participants were from Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth Israel Deaconess Medical Center, Duke University Medical Center, and MD Anderson Cancer Center. The discussion focused on three main themes: epidemiology, detection, and pathology; state of the science including the biology of DCIS and potential novel treatment approaches; and risk perceptions, communication, and decision-making. Here we summarize the proceedings from this event.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.